Research & Diagnostics
Lung cancers are driven by SNVs in genes like EGFR as well as fusions in ALK, ROS1, RET and other genes. Since these mutations can be targeted by specific therapies, accurate and complete detection of variants in all these genes is important as companion diagnostics. TLA enables detection of all translocations and small mutations in these genes in a single DNA-based NGS test.
Among solid tumours, clinical development of ctDNA testing for therapy response monitoring is most advanced in lung cancer. Such tests are currently mostly based on the detection of SNVs. TLA uniquely enables detection of gene fusion breakpoint sequences at nucleotide resolution. Since gene fusions of ALK, ROS, NTRK, etc. are known to be cancer-driving clonal events, these breakpoint sequences are ideal markers for sensitive ctDNA testing with PCR.
Become a testing partner
We are currently further validating this application. Please contact us if you would like to become a testing partner.
- Application notes
Macintyre G et al. (2016)
University of Cambridge & VU University Medical Center
Hastings RJ et al. (2015)
Charles University Prague, CHUV, Great Ormond St Hospital, Gustave Roussy, Hospital del Mar, Institute of Genomic Medicine, Oslo University Hospital, Ospedale di Circolo-Polo Universitario, Our Lady's Children's Hospital, Oxford University Hospitals NHS Trust, Radboud University Medical Center, St James's Hospital, University of Cagliari, University of Groningen, University Hospital Ghent, UZ Leuven, VU University Medical Center
De Vree PJP et al. (2014)
Cergentis, Erasmus Medical Center, Ghent University, Hubrecht Institute-KNAW, Leiden University Medical Center, The Netherlands Cancer Institute, Radboud University Medical Center, University of Amsterdam, University of Groningen, University Medical Center Utrecht & VIB
Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma
Genuardi E et al. (2017)
A.O.U. Citta della Salute e della Scienza di Torino, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Cergentis, Clinica Humanitas/Gavazzeni, University of Modena e Reggio Emilia & University of Torino
Dogliotti I & Ferrero S (2017)
A.O.U. Citta della Salute e della Scienza di Torino & University of Torino
Meisel C et al. (2017)
DKFZ, Medical Genetic Center Munich, National Center for Tumor Diseases (NCT), TU Dresden, University Kiel
Toy W et al. (2016)
AstraZeneca, Memorial Sloan Kettering Cancer Center, University of Chicago & University of Illinois at Urbana Champaign
Ter Brugge P et al. (2016)
Bellvitge Biomedical Research Institute Barcelona, Curie Institute, ICREA, Institute of Cancer Research London, The Netherlands Cancer Institute, University of Barcelona & University Medical Center Utrecht
Applications and principles of TLA-based complete gene sequencing and haplotyping